US · ILMN · MEDICAL - DIAGNOSTICS & RESEARCH
Illumina, Inc. (ILMN) intrinsic value and stock valuation
$192.82as of 2026-11-21 · Mkt cap 28.44B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Illumina, Inc. DCF and intrinsic value
InvestorsCraft values ILMN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ILMN’s statements →
Illumina, Inc. Graham Number
Graham Number: $46.56d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2010–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Waters Corporation (WAT) $440.45
- Quest Diagnostics Incorporated (DGX) $258.28
- Labcorp Holdings Inc. (LH) $367.13
- West Pharmaceutical Services, Inc. (WST) $390.30
- Tenet Healthcare Corporation (THC) $263.19
- Genmab A/S (GMAB) $50.60
- Zimmer Biomet Holdings, Inc. (ZBH) $101.10
- Medpace Holdings, Inc. (MEDP) $610.54
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.37B | $4.5B | $4.53B | $3.24B |
| Operating income | $864M | -$-833M | -$-1.07B | -$-123M | $580M |
| Net income | $850M | -$-1.22B | -$-1.16B | $762M | $656M |
| EPSd | $5.45M | -$-7.69M | -$-7.35M | $5.05M | $4.43M |
| Operating cash flow | $1.08B | $837M | $478M | $545M | $1.08B |
| Capital expenditure | -$-148M | -$-128M | -$-195M | -$-208M | -$-189M |
| Free cash flow | $931M | $709M | $282M | $337M | $891M |
| Total assets | $6.64B | $6.3B | $10.1B | $15.2B | $7.59B |
| Total debt | $2.55B | $2.62B | $2.26B | $2.54B | $1.91B |
| Net debt | $1.14B | $1.5B | $1.21B | $1.31B | $96M |
| Total equity | $2.72B | $2.37B | $5.75B | $10.7B | $4.69B |
| Cash and short-term investments | $1.63B | $1.22B | $1.05B | $1.34B | $3.47B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.37B | $4.5B | $4.53B | $3.24B |
| Cost of revenue | $1.45B | $1.51B | $1.76B | $1.37B | $1.04B |
| Gross profit | $2.89B | $2.86B | $2.74B | $3.15B | $2.2B |
| Research and development expenses | $951M | $1.17B | $1.35B | $1.19B | $682M |
| Selling, general and administrative expenses | $1.08B | $1.09B | $1.61B | $2.09B | $941M |
| Other expenses | $0.00 | $1.43B | $847M | $0.00 | $0.00 |
| Operating expenses | $2.03B | $3.69B | $3.81B | $3.28B | $1.62B |
| Cost and expenses | $3.47B | $5.21B | $5.57B | $4.65B | $2.66B |
| Interest income | $40M | $46M | $58M | $0.00 | $41M |
| Interest expense | $101M | $100M | $77M | $61M | $49M |
| Depreciation and amortization | $270M | $354M | $432M | $251M | $187M |
| Ebitda | $1.46B | -$-725M | -$-608M | $1.2B | $1.09B |
| Operating income | $864M | -$-833M | -$-1.07B | -$-123M | $580M |
| Total other income/expenses, net | $222M | -$-346M | -$-48M | $1.01B | $276M |
| Income before tax | $1.09B | -$-1.18B | -$-1.12B | $884M | $856M |
| Income tax expense | $236M | $44M | $44M | $122M | $200M |
| Net income | $850M | -$-1.22B | -$-1.16B | $762M | $656M |
| Weighted average shares outstanding | $155M | $159M | $158M | $150M | $147M |
| Weighted average diluted shares outstanding | $156M | $159M | $158M | $151M | $148M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.63B | $1.22B | $1.05B | $1.34B | $3.47B |
| Net receivables | $854M | $751M | $752M | $664M | $487M |
| Inventory | $564M | $547M | $587M | $431M | $372M |
| Total current assets | $3.29B | $2.75B | $2.61B | $2.71B | $4.48B |
| Property, plant and equipment, net | $1.13B | $1.23B | $1.55B | $1.7B | $1.45B |
| Goodwill and intangible assets | $1.32B | $1.41B | $5.54B | $10.4B | $1.04B |
| Long-term investments | $338M | $227M | $196M | $213M | $418M |
| Total non-current assets | $3.36B | $3.56B | $7.5B | $12.5B | $3.1B |
| Total assets | $6.64B | $6.3B | $10.1B | $15.2B | $7.59B |
| Accounts payable | $240M | $221M | $245M | $332M | $192M |
| Short-term debt | $577M | $578M | $86M | $71M | $562M |
| Deferred revenue | $270M | $260M | $252M | $234M | $186M |
| Total current liabilities | $1.59B | $1.55B | $1.57B | $1.09B | $1.24B |
| Long-term debt | $1.98B | $2.04B | $2.18B | $2.47B | $1.34B |
| Deferred revenue, non-current | $0.00 | $67M | $0.00 | $0.00 | $44M |
| Total non-current liabilities | $2.34B | $2.38B | $2.8B | $3.38B | $1.65B |
| Capital lease obligations | $564M | $554M | $773M | $845M | $671M |
| Total liabilities | $3.92B | $3.93B | $4.37B | $4.48B | $2.89B |
| Common stock | $2M | $2M | $2M | $2M | $2M |
| Retained earnings | -$-392M | -$-1.24B | -$-19M | $5.49B | $4.72B |
| Accumulated other comprehensive income (loss) | -$-10M | $22M | -$-1M | $17M | $2M |
| Total equity | $2.72B | $2.37B | $5.75B | $10.7B | $4.69B |
| Total investments | $553M | $320M | $202M | $320M | $2.08B |
| Total debt | $2.55B | $2.62B | $2.26B | $2.54B | $1.91B |
| Net debt | $1.14B | $1.5B | $1.21B | $1.31B | $96M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $850M | -$-1.22B | -$-1.16B | $762M | $656M |
| Depreciation and amortization | $270M | $354M | $432M | $251M | $187M |
| Stock-based compensation | $275M | $370M | $380M | $754M | $194M |
| Change in working capital | -$-153M | -$-483M | -$-90M | -$-152M | $73M |
| Accounts receivable | -$-108M | -$-25M | -$-40M | -$-164M | $89M |
| Inventory | -$-17M | $19M | -$-20M | -$-58M | -$-12M |
| Accounts payable | $2M | -$-4M | -$-44M | $60M | $40M |
| Net cash provided by operating activities | $1.08B | $837M | $478M | $545M | $1.08B |
| Investments in property, plant and equipment | -$-148M | -$-128M | -$-195M | -$-208M | -$-189M |
| Acquisitions, net | -$-10M | $2M | -$-29M | -$-2.44B | -$-98M |
| Net cash used for investing activities | -$-55M | -$-178M | -$-231M | -$-1.07B | -$-554M |
| Common stock issued | $44M | $56M | $67M | $60M | $61M |
| Common stock repurchased | -$-742M | -$-116M | $0.00 | $0.00 | -$-736M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-744M | -$-570M | -$-1.21B | -$-51M | -$-766M |
| Net change in cash | $291M | $79M | -$-963M | -$-578M | -$-232M |
| Cash at end of period | $1.42B | $1.13B | $1.05B | $1.23B | $1.81B |
| Operating cash flow | $1.08B | $837M | $478M | $545M | $1.08B |
| Capital expenditure | -$-148M | -$-128M | -$-195M | -$-208M | -$-189M |
| Free cash flow | $931M | $709M | $282M | $337M | $891M |
Line items
Line items
Line items
About Illumina, Inc.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
- CEO
- Jacob Thaysen
- Employees
- 8.6K
- Beta
- 1.47
Included in
Explore
Frequently asked questions
What is the intrinsic value of Illumina, Inc. (ILMN)?
Illumina, Inc. (ILMN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ILMN undervalued?
ILMN trades at a price of $192.82 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.